

REMARKS

New claims 72-148 have been added. Of these new claims, claims 72, 96, and 125 are independent.

New independent claim 72 is directed to sustained release dosage forms characterized by the in vitro dissolution criteria for determining a sustained release dosage form according to the invention. It is supported by the text appearing in the specification at page 40, line 33 to page 41, line 2, and also by the text at page 41, line 26 to page 42, line 6. Claim 72 essentially expresses an in vitro release rate for a mammal of about 50 Kg. See Applicants' specification at page 3, lines 14-26, especially at line 26.

New dependent claims 73-95 define sustained release embodiments which parallel those defined by claims 3 through 21 and 59 through 62 in the parent application.

New independent claim 96 is directed to delayed release dosage forms characterized by the in vitro criteria for determining a delayed release dosage form according to the invention. It is supported by the text appearing in the specification at page 40, line 33 to page 41, line 2, and also by the text at page 42, lines 7-25.


New dependent claims 96-124 define delayed release embodiments which parallel those defined by claims 28 through 55 in the parent application.

New independent claim 125 is directed to sustained release dosage forms characterized by the in vitro dissolution criteria for determining a sustained release dosage form according to the invention. Claim 125 parallels claim 72 and is therefore supported in the same manner as claim 72, i.e., by the text appearing in the specification at page 40, line 33 to page 41, line 2, and also by the text at page 41, line 26 to page 42, line 6. Instead of expressing the in vivo criteria in terms of a 50 Kg mammal as does claim 72, claim 125 expresses the in vivo criteria in terms of mg/Kg, in parallel with the criteria of original claim 1, and thus is not limited to a mammal of any particular size. Claim 125 is thus drafted in parallel with claim 72, but differs therefrom in that it expresses its in vitro criteria in parallel with the in vivo criteria of original claim 1, by which it is accordingly also supported.

Action on the merits, especially a Notice of Allowance, is respectfully requested.

Respectfully submitted,

DATE: May 22, 2000


James T. Jones
Agent for the Applicants
Reg. No. 30,561

Pfizer Inc.
Patent Dept.
Eastern Point Road
Groton, CT. 06340
(860)441-4903

002250" 65077560